Social anxiety disorder - A review of pharmacological treatments

Current Psychiatry Reviews

Volumn 3, Issue 2, 2007, Pages 95-122

  Robinson, Hayley M ^a   Hood, Sean D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Benzodiazepine; Clinical Global Impressions Improvement (CGI I); DSM IV; Liebowitz Social Anxiety Scale; Monoamine oxidase inhibitor; Neuropeptides; Specific serotonin reuptake inhibitor

Indexed keywords

ALPRAZOLAM; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BROMAZEPAM; CHOLECYSTOKININ; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DOPAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y; NORADRENALIN; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; UNINDEXED DRUG; VENLAFAXINE; VOFOPITANT;

ANOREXIA; ANORGASMIA; ANXIETY; BEHAVIOR THERAPY; BODY WEIGHT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED DRUG RELEASE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; EVIDENCE BASED MEDICINE; FATIGUE; FEAR; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INSOMNIA; LIBIDO DISORDER; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RESTLESSNESS; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL AVOIDANCE BEHAVIOR; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL PHOBIA; SOMNOLENCE; SWEATING; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; UNSTEADINESS; XEROSTOMIA;

EID: 34248678464     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340007780599069     Document Type: Review

References (197)

1. Hood SD. Silent social anxiety disorder. The West Australian, 19. 11-5-2000. Perth, Australia.
2. Williams K. Embarrassing claim by psychiatrists. The West Australian, 15. 4-5-2000. Perth, Australia.
3. Argyropoulos SV, Hood SD, Nutt DJ. Social phobia: illness or illusion? Acta Psychiatr Scand 2001; 103: 241-243.
4. Rettew DC. Avoidant personality disorder, generalized social phobia, and shyness: putting the personality back into personality disorders. Harv Rev Psychiatry 2000; 8: 283-297.
5. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-596.
6. Nutt DJ. Death by tricyclic: the real antidepressant scandal? J Psychopharmacol 2005; 19: 123-124.
7. Ringold AL. Paroxetine efficacy in social phobia. J Clin Psychiatry 1994; 55: 363-364.
8. Mancini C, Ameringen MV. Paroxetine in social phobia. J Clin Psychiatry 1996; 57: 519-522.
9. Stein MB, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996; 16: 218-222.
10. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280: 708-713.
11. Montgomery SA. Implications of the severity of social phobia. J Affect Disord 1998; 50 Suppl 1: S17-S22.
12. Stein DJ, Berk M, Els C, et al. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 1999; 89: 402-406.
13. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999; 175: 120-126.
14. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acts, Psychiatr Scand 1999; 100: 193-198.
15. Allgulander C, Nilsson B. A prospective study of 86 new patients with social anxiety disorder. Acts, Psychiatr Scand 2001; 103: 447-452.
16. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002; 63: 66-74.
17. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002; 59: 1111-1118.
18. Stein DJ, Stein MB, Goodwin W, Kumar R, Hunter B. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology (Berl) 2001; 158: 267-272.
19. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 2004; 65: 1696-1707.
20. Baldwin D. Paroxetine for social anxiety disorder: Review of three randomised, double-blind, placebo-controlled. studies (Abstract). Eur Neuropsychopharmacol 1999; 9(Supplemcnt 5).
21. Roy-Byrne P, Perera P, Pitts CD, Christi JA. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. J Clin Psychiatry 2005; 66: 1228-1233.
22. Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19: 387-396.
23. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65: 244-248.
24. Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19: 241-248.
25. Stein DJ, Andersen EW, Lader M. Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions. Eur Neuropsychopharmacol 2006; 16: 33-38.
26. Stein DJ, Kasper S, Andersen EW, Nil R, Lader M. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. Depress Anxiety 2004; 20: 175-181.
27. Lepine JP, Pelissolo A. Social phobia and alcoholism: a complex relationship. J Affect Disord 1998; 50 Suppl 1: S23-S28.
28. Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001; 14: 255-262.
29. Lepola U, Bergtholdt B, St LJ, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004; 65: 222-229.
30. Sternbach H. Fluoxetine treatment of social phobia. J Clin Psychopharmacol 1990; 10: 230-231.
31. Schneier FR, Chin SJ, Hollander E, Liebowitz MR. Fluoxetine in social phobia. J Clin Psychopharmacol 1992; 12: 62-64.
32. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 1992; 12: 293-295.
33. Van Ameringen MA, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993; 54: 27-32.
34. Koponen H, Lepola U, Juhani LEV. Fluoxetine in social phobia: a pilot study. Presented at the 15th National Conference of the Anxiety Disorders Association of America. 1995. Pittsburgh, PA.
35. Perugi G, Nassini S, Lenzi M, Simonini E, Cassano GB, McNair DM. Treatment of social phobia with fluoxetine. Anxiety 1994; 1: 282-286.
36. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002; 22: 257-262.
37. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71: 1058-1067.
38. Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61: 1005-1013.
39. Birmaher B, Waterman GS, Ryan N, et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994; 33: 993-999.
40. Fairbanks JM, Pine DS, Tancer NK, et al. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol 1997; 7: 17-29.
41. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42: 415-423.
42. Lepola U, Koponen H, Leinonen E. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry 1994; 27: 186-188.
43. Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998; 49: 79-82.
44. Simon NM, Sharma SG, Worthington JJ, Marzol PC, Pollack MH. Citalopram for social phobia: a clinical case series. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 1469-1474.
45. Simon NM, Korbly NB, Worthington JJ, Kinrys G, Pollack MH. Citalopram for Social Anxiety Disorder: An Open-label Pilot Study in Refractory and Nonrefractory Patients. CNS Spectr 2002; 7: 655-657.
46. Varia IM, Cloutier CA, Doraiswamy PM. Treatment of social anxiety disorder with citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 205-208.
47. Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobremide in patients with social phobia: some preliminary findings. Hum Psychopharmacol 2002; 17: 401-405.
48. Schneier FR, Blanco C, Campeas R, et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety 2003; 17: 191-196.
49. Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Tunckol H. Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci 2004; 254: 231-235.
50. Kosieradzki PH. Citalopram in social phobia. J Am Acad Child Adolesc Psychiatry 2001; 40: 1126-1127.
51. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
52. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-392.
53. File SE. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology (Berl) 2000; 152: 105-109.
54. Varty GB, Cohen-Williams ME, Morgan CA, et al. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 2002; 27: 371-379.
55. Furmark T, Appel L, Michelgård A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005; 58: 132-142.
56. Warwick JM, Carey P, van der Linden GJ, et al. A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. Metab Brain Dis 2006.
57. Montgomery SA, Durr-Pal N, Loft H, Nil R. Relapse prevention by escitalopram treatment of patient with social anxiety disorder (SAD). Eur Neuropsychopharmacol 2003; 13S4: 364.
58. Montgomery SA, Nil R, Drr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270-1278.
59. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186.
60. Lele M, Joglekar A. Escitalopram for social anxiety disorder. Br J Psychiatry 2005; 187: 290-292.
61. Van Ameringen MA, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994; 31: 141-145.
62. Munjack DJ, Flowers C, Eagan TV. Sertraline in social phobia. Anxiety 1994; 1: 196-198.
63. Martins EA, Pigott TA, Bernstein SE, et al. Sertraline in the treatment of patients with social phobia. Anxiety 1994; 1: 291-297.
64. Czepowicz VD, Johnson MR, Lydiard RB, et al. Sertraline in social phobia. J Clin Psychopharmacol 1995; 15: 372-373.
65. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152: 1368-1371.
66. Van Ameringen MA, Swinson RP, Walker JR, Lane RM. A placebo-controlled study of sertraline in generalised social phobia. J Eur Coll Neuropsychopharmacol 1999; 9(S5): S235.
67. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275-281.
68. Van Ameringen MA, Oakman J, Mancini C, Pipe B, Chung H. Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol 2004; 24: 42-48.
69. Blomhoff S, Haug TT, Hellstrom K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179: 23-30.
70. Haug TT, Blomhoff S, Hellstrom K, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 2003; 182: 312-318.
71. Bandelow B. Sertraline and exposure therapy in social phobia. Br J Psychiatry 2004; 184: 271-272.
72. Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 785-792.
73. Connor KM, Davidson JR, Chung H, Yang R, Clary CM. Multidimensional effects of sertraline in social anxiety disorder. Depress Anxiety 2006; 23: 6-10.
74. Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 564-571.
75. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994; 115: 128-134.
76. Den-Boer JA, van Vliet IM, Westenberg HGM. Recent advances in the psychopharmacology of social phobia. Progress in Neuropsychopharmacol Biol Psychiatry 1994; 18: 625-645.
77. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156: 756-760.
78. DeVane CL, Ware MR, Emmanuel NP. The evaluation of the safety, efficacy, and physiological effects of fluvoxamine in social phobia. Presented at the 24th Annual Meeting of the American College of Neuropsychopharmacology. 1995. San Juan, Puerto Rico. 11-12-1995.
79. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344: 1279-1285.
80. Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2006; In press.
81. Davidson JR, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 118-125.
82. Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 49-55.
83. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26: 25-40.
84. Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003; 6: 317-323.
85. Kobayashi N, Kurauchi S, Sawamura T, Shigemura J, Sano SY, Nomura S. The effect of paroxetine on Taijinkyofusho: a report of three cases. Psychiatry 2003; 66: 262-267.
86. Matsunaga H, Kiriike N, Matsui T, Iwasaki Y, Stein DJ. Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors? Int J Neuropsychopharmacol 2001; 4: 231-237.
87. Nagata T, Van VI, Yamada H, Kataoka K, Iketani T, Kiriike N. An open trial of paroxetine for the "offensive subtype" of taijin kyofusho and social anxiety disorder. Depress Anxiety 2006; 23: 168-174.
88. Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM. The efficacy of selective serotonin reuptake, inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2006; 21: 102-111.
89. van der Linden GJ, Stein DJ, Van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15 Suppl 2: S15-S23.
90. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995; 31: 767-771.
91. Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999; 14: 239-245.
92. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 488-496.
93. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 238-247.
94. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62: 190-198.
95. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacol (Berl) 2004; 177: 280-288.
96. Atmaca M, Tezcan E, Kuloglu M. An open clinical trial of reboxetine in the treatment of social phobia. J Clin Psychopharmacol 2003; 23: 417-419.
97. Pacchiarotti I, Manfredi G, Kotzalidis GD, Ruberto A, Tatarelli R, Girardi P. A case of social phobia and avoidant personality disorder with erectile dysfunction successfully treated with venlafaxine and add-on reboxetine. Eur Psychiatry 2004; 19: 233-234.
98. Liebowitz MR, Gorman J, Fyer A, et al. Psychopharmacological treatment of social phobia. Psychopharmacol Bull 1985; 21: 610-614.
99. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A. Phenelzine in social phobia. J Clin Psychopharmacol 1986; 6: 93-98.
100. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49: 290-300.
101. Liebowitz MR, Gorman JM, Fyer AJ, et al. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988; 49: 252-257.
102. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine and atenolol in social phobia. Psychopharmacol Bull 1990; 26: 123-125.
103. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991; 48: 938-945.
104. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353-360.
105. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55: 1133-1141.
106. Heimberg RG, Dodge CS, Hope DA, Kennedy CR, Zollo I, Becker RE. Cognitive behavioral group treatment of social phobia: comparison with a credible placebo control. Cogn Ther Res 1990; 14: 1-23.
107. Liebowitz MR, Heimberg RG. Issues in the design of trials for the evaluation of psychopharmacological treatments for social phobia. Int Clin Psychopharmacol 1996; 11 Suppl 3: 49-53.
108. Liebowitz MR, Heimberg RG, Schneier FR, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999; 10: 89-98.
109. Golwyn DH, Weinstock RC. Phenelzine treatment of elective mutism: a case report. J Clin Psychiatry 1990; 51: 384-385.
110. Golwyn DH, Sevlie CP. Phenelzine treatment of selective mutism in four prepubertal children. J Child Adolesc Psychopharmacol 1999; 9: 109-113.
111. Aarrc TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry 2003; 57: 313-315.
112. Versiani M, Mundim FD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988; 8: 279-293.
113. Versiani M, Nardi AE, Mundim FD. Fobia social. J Bras Psiquiatr 1989; 38: 251-263.
114. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992; 2: 21-29.
115. Slaap BR, van Vliet IM, Westenberg HG, den Boer JA. Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J Affect Disord 1996; 39: 13-19.
116. Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatry Scand 1995; 92: 351-358.
117. Fahlen T. Personality traits in social phobia, II: Changes during drug treatment. J Clin Psychiatry 1995; 56: 569-573.
118. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997; 17: 255-260.
119. Bisserbe JC, Lepine JP. Moclobemide in social phobia: a pilot open study. GRP Group. Groupe de Recherche en Psychopharmacologie. Clin Neuropharmacol 1994; 17 Suppl 1: S88-S94.
120. Katschnig H, Stein MB, Buller R. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 71-80.
121. Noyes R, Jr., Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17: 247-254.
122. Nutt DJ, Montgomery SA. Moclobemide in the treatment of social phobia. Int Clin Psychopharmacol 1996; 11 Suppl 3: 77-82.
123. Blanco C, Liebowitz MR. Dimensional versus categorical response to moclobemide in social phobia. J Clin Psychopharmacol 1998; 18: 344-346.
124. Versiani M, Amrein R, Montgomery SA. Social phobia: long-term treatment outcome and prediction of response-a moclobemide study. Int Clin Psychopharmacol 1997; 12: 239-254.
125. Versiani M, Nardi AE, Mundim FD, Pinto S, Saboya E, Kovacs R. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 1996; 11 Suppl 3: 83-88.
126. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172: 70-77.
127. Duffett R. Moclobemide in social phobia. Br J Psychiatry 1998; 172: 451-452.
128. Oosterbaan DB, Van Balkom AJ, Spinhoven P, van Oppen P, van Dyck R. Cognitive therapy versus moclobemide in social phobia: A controlled study. Clin Psychol Psychother 2001; 8: 263-273.
129. Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 2002; 17: 161-170.
130. Perugi G, Akiskal HS, Toni C, Simonini E, Gemignani A. The temporal relationship between anxiety disorders and (hypo)mania: a retrospective examination of 63 panic, social phobic and obsessive-compulsive patients with comorbid bipolar disorder. J Affect Disord 2001; 67: 199-206.
131. Nutt DJ. Making sense of GABA(A) receptor subtypes: is a new nomenclature needed? J Psychopharmacol 2005; 19: 219-220.
132. Lydiard RB, Laraia MT, Howell EF, Ballenger JC. Alprazolam in the treatment of social phobia. J Clin Psychiatry 1988; 49: 17-19.
133. Reich J, Yates W. A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry 1988; 145: 590-594.
134. Reiter SR, Pollack MH, Rosenbaum JF, Cohen LS. Clonazepam for the treatment of social phobia. J Clin Psychiatry 1990; 51: 470-472.
135. Ontiveros A, Fontaine R. Social phobia and clonazepam. Can J Psychiatry 1990; 35: 439-441.
136. Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appleton AA. Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry 1990; 51 Suppl: 35-40.
137. Davidson JR, Ford SM, Smith RD, Potts NL. Long-term treatment of social phobia with clonazepam. J Clin Psychiatry 1991; 52(Supplement): 16-20.
138. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13: 423-428.
139. Sutherland SM, Tupler LA, Colket JT, Davidson JR. A 2-year follow-up of social phobia. Status after a brief medication trial. J Nerv Ment Dis 1996; 184: 731-738.
140. Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998; 18: 373-378.
141. Fallon B, Lloyd GG, Harpin RE. The treatment of social phobia: Real-life rehearsal with non-professional therapists. J Nerv Ment Dis 1981; 169: 180-184.
142. Gorman JM, Liebowitz MR, Fyer AJ, Campeas R, Klein DF. Treatment of social phobia with atenolol. J Clin Psychopharmacol 1985; 5: 298-301.
143. Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994; 62: 350-358.
144. Hood SD, Argyropoulos SV, Nutt DJ. New directions in the treatment of anxiety disorders. Exp Opin Ther Patents 2003; 13: 401-424.
145. van Vliet IM, Westenberg HG, Slaap BR, den Boer JA, Ho Pian KL. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol Psychiatry 1997; 42: 76-78.
146. McCann UD, Morgan CM, Geraci M, Slate SO, Murphy DL, Post RM. Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 1997; 17: 360-369.
147. Tancer ME, Stein MB, Gelernter CS, Uhde TW. The hypothalamic-pituitary-thyroid axis in social phobia. Am J Psychiatry 1990; 147: 929-933.
148. Cowley DS, Adams JB, Pyke RE, et al. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Biol Psychiatry 1996; 40: 550-552.
149. Adams JB, Pyke RE, Costa J, et al. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995; 15: 428-434.
150. Stein MB, Hauger RL, Dhalla KS, Chartier MJ, Asmundson GJ. Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia. Psychiatry Res 1996; 59: 183-188.
151. Den-Boer JA, van Vliet IM, Westenberg HGM. Recent developments in the psychopharmacology of social phobia. European Arch Psychiatry Clin Neurosci 1995; 244: 309-316.
152. Emmanuel N, Johnson M, Villareal G, et al. Imipramine in the Treatment of Social Phobia, A Double-Blind Study. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology. 8-12-1997. Kohala Coast, Hawaii.
153. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998; 18: 132-135.
154. Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991; 148: 598-605.
155. Schneier FR, Saoud JB, Campeas R, et al. Buspirone in social phobia. J Clin Psychopharmacol 1993; 13: 251-256.
156. Munjack DJ, Bruns J, Baltazar PL. A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord 1991; 5: 87-98.
157. Zwier KJ, Rao U. Buspirone use in an adolescent with social phobia and mixed personality disorder (cluster A type). J Am Acad Child Adolesc Psychiatry 1994; 33: 1007-1011.
158. van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997; 58: 164-168.
159. Van Ameringen MA, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996; 39: 115-121.
160. 3 antagonist, ondansetron in social phobia. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. 1999. San Juan, Puerto Rico. 12-12-1994.
161. Emmanuel NP, Lydiard RB, Ballenger JC. Treatment of social phobia with bupropion. J Clin Psychopharmacol 1991; 11: 276-277.
162. Goldstein S. Treatment of social phobia with clonidine. Biol Psychiatry 1987; 22: 369-372.
163. Newcorn JH, Schulz K, Harrison M, DeBellis MD, Udarbe JK, Halperin JM. Alpha 2 adrenergic agonists: Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am 1998; 45: 1099.
164. Worthington JJ, III, Zucker BG, Fones CS, Otto MW, Pollack MH. Nefazodone for social phobia: a clinical case series. Depress Anxiety 1998; 8: 131-133.
165. Van Ameringen MA, Mancini C, Oakman JM. Nefazodone in social phobia. J Clin Psychiatry 1999; 60: 96-100.
166. Van Veen JF, van Vliet IM, Westenberg HG. Mirtazapine in social anxiety disorder: a pilot study. Int Clin Psychopharmacol 2002; 17: 315-317.
167. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 580-583.
168. Pande AC, Pollack MH, Crockatt J, et al. Placebo-oontrolled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467-471.
169. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341-348.
170. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24: 141-149.
171. Simon NM, Worthington J, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004; 65: 1219-1222.
172. Zhang W, Connor KM, Davidson JR. Lovetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 2005; 19: 551-553.
173. Van Ameringen MA, Mancini C, Pipe B, Oakman J, Bennett M. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004; 65(12).
174. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003; 18: 169-172.
175. Camacho A, Stein MB. Modafinil for social phobia and amphetamine dependence. Am J Psychiatry 2002; 159: 1947-1948.
176. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16: 365-368.
177. Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry 2005; 66: 540-542.
178. Stravynski A, Lamontagne Y, Lavallee YJ. Clinical phobias and avoidant personality disorder among alcoholics admitted to an alcoholism rehabilitation setting. Can J Psychiatry 1986; 31: 714-719.
179. Naftolowitz DF, Vaughn BV, Ranc J, Tancer ME. Response to alcohol in social phobia. Anxiety 1994; 1: 96-99.
180. Himle JA, Abelson JL, Haghightgou H, Hill EM, Nesse RM, Curtis GC. Effect of alcohol on social phobic anxiety. Am J Psychiatry 1999; 156: 1237-1243.
181. Abrams K, Kushner MG. The moderating effects of tension-reduction alcohol outcome expectancies on placebo responding in individuals with social phobia. Addict Behav 2004; 29: 1221-1224.
182. Hood SD, Nutt DJ. How I Treat - St John's Wort. The Practitioner 243, 779-786. 1999. London, Miller Freeman UK Ltd.
183. Perovic S, Muller W. Pharmacological profile of hypericum extract effect on serotonin uptake by postsynaptic receptors. Arzneim-Forsch (Drug Res) 1995; 45: 1145-1148.
184. Muller W, Rolli M, Schafter C, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30(suppl 2).
185. Cott JM. In vitro receptor binding and enzyme inhibition by Hypercium perforatum extract. Pharmacopsychiatry 1997; 30(Suppl 2): 102-107.
186. Kobak KA, Taylor LV, Warner G, Futterer R. St John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005; 25: 51-58.
187. Boerner RJ. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia. Phytother Res 2001; 15: 646-647.
188. Trendelenburg G, Heinz A, Strohle A. Gamma-hydroxybutyrate dependence with social phobia. Am J Psychiatry 2004; 161: 375-376.
189. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63: 298-304.
190. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158: 1725-1727.
191. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 2001; 21: 311-324.
192. Blanco C, Schneier F, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 2003; 18: 29-40.
193. Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Sys Rev 2004; 4.
194. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59 Suppl 17: 54-60.
195. Christmas DM, Hood SD. Recent Developments in Anxiety Disorders. Recent Pat CNS Drug Discov 2006; 1: 289-298.
196. Mancini C, Van-Ameringen M, Oakman JM, Farvolden P. Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. Depress Anxiety 1999; 10: 33-39.
197. Lehman RB. Rapid resolution of social anxiety disorder, selective mutism, and separation anxiety with paroxetine in an 8-year-old girl. J Psychiatry Neurosci 2002; 27(2): 124-125.